11:45 AM EDT, 08/07/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday it received approval from the European Commission for Adzynma for the treatment of congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.

Takeda said the EC approval does not have any impact on its consolidated forecast for the fiscal year ending March 31, 2025.

Shares of the company were up about 4% in recent trading.

Price: 13.84, Change: +0.53, Percent Change: +3.94